Coronary heart disease (CHD) is the leading cause of death in men over the age of 45 years and women over the age of 65 years in Europe.' As a result, attempts to reduce this burden of disease are of paramount importance, and a reduction in the occurrence and progression of CHD remain major goals of preventive medicine. The UK Government's Health of the nation document sets a target for reducing mortality from CHD in people under 65 The aim of dietary modification is to reduce fat intake so that no more than 30% of total dietary calories are fat-derived.4 Saturated fat should be restricted to less than 10% of total calorie intake, especially as saturated fat intake raises plasma cholesterol levels and increases the hypercholesterolaemic effect of dietary cholesterol. In addition, cholesterol intake should be restricted to 300 mg/day for an adult, and part of the diet replaced by complex carbohydrate, particularly soluble fibre. What these dietary targets mean in terms of usual diet is beyond the scope of this article, but useful diet fact sheets are available from dieticians.
In practice, dietary modifications have proved disappointing. Long-term clinical studies have shown a reduction in cholesterol achieved through voluntary dietary modification to be no more than 2%. '7-20 DRUG THERAPY Several drug classes are available to clinical practice to reduce cholesterol levels. These include anion-exchange resins (cholestyramine, colestipol), probucol, fibric acid derivatives (clofibrate, bezafibrate, ciprofibrate, fenofibrate, gemfibrozil), nicotinic acid and its analogues, and statins (pravastatin, simvastatin, etc). These agents, especially the statins, give substantial (up to 25%) reductions in cholesterol levels. They are extremely effective at reducing cholesterol levels and have been the drugs used in the very effective primary and secondary prevention trials reviewed above. The choice of which drug to use should take into consideration the nature of the underlying lipid metabolism abnormality. Simvastatin and pravastatin, in addition to their proven role in secondary prevention of CHD, are also first-line treatments for individuals who have a pure or combined hypercholesterolaemia, excluding children and women of child-bearing potential. The anticipated benefit of lipid-lowering medication must be weighed, however, against the cost and patient resistance to long-term drug therapy, as well as the possibility and fear of side-effects. 4 The fear of side-effects is probably exaggerated; reports of rhabdomyolysis and very high creatine kinase levels have only been isolated cases and the incidence of side-effects in the large randomised trials has been very low. Nevertheless, fear of (perceived) side-effects remains a major reason for poor patient compliance. 
